RECRUITING Not applicable ClinicalTrials.gov

Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer

Sponsor: Centre Francois Baclesse • ClinicalTrials.gov ID: NCT05414357

Registry updated: 2026-09-30

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Patients treated for breast cancer frequently complain of sleep disturbances, about 40% of them. Of the sleep disturbances experienced by patients, insomnia is the most common complaint. The prevalence of insomnia complaints is higher in breast cancer patients compared to other types of cancer, and is also higher than in the general population (between 20% and 70% in breast cancer patients vs 30% in the general population). A recent study indicates that sleep complaints concern 25% of patients even before diagnosis, and 46% (including 18% complaining of insomnia) at the time of diagnosis, showing the negative impact of the announcement of the pathology on the subjective quality of sleep, and particularly on symptoms suggestive of insomnia. However, objective information on a modification of sleep patterns in breast cancer remains scarce and does not allow us to conclude. In particular, previous studies have focused only on the effects of chemotherapy and have not always included a control group, limiting the significance of their results. The links with cognitive and psychopathological processes and the underlying mechanisms are not clearly demonstrated in this pathology. Finally, taking into account patients' complaints, it appears necessary to limit sleep disorders in breast cancer in order to improve patients' quality of life using non-medicinal and easy-to-implement approaches.

Interventions

Functional Magnetic Resonance Imaging at rest and in activation with attentional task (Diagnostic test)
Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include: * Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2). * Biological and physiological measurements * Spatial memory task * Cognitive battery * Questionnaires (sleep, quality of life)

Eligibility criteria

Inclusion Criteria: * Patients aged 39 to 69 years * A patient with localized breast cancer who has undergone surgery and may or may not be about to begin adjuvant treatment with chemotherapy or radiation therapy * Patient with education level 3 "end of primary education" * Patient with a good command of the French language * Patient with access to the Internet from a computer at home * Patient having signed the consent to participate in the study * Patient with no pre-existing cognitive impairment at the time of cancer diagnosis * Patient with a sleep complaint (ISI \> 7) Exclusion Criteria: * Patient with metastatic cancer * A patient with a primary cancer other than breast cancer and/or a history of treated cancer * Patient with a history of neurological damage * Patient with treated sleep apnea * Patient with drug use or alcohol abuse (≥3 drinks/day on average and/or \>10 drinks/week) * Patient with a treatment that has not been stabilized for at least 3 months (hypnotics, antidepressants, anxiolytics) * Patient with a personality disorder and/or an evolving psychiatric pathology * Patient with a contraindication to MRI (claustrophobia, metallic objects in the body) * Patient with an uncorrected vision problem

Conditions

Breast Cancer Sleep Quality of Life

Locations

Centre François Baclesse — Caen, France
Inserm-Ephe-Unicaen U1077 — Caen, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment